Category

Archives

VEGFR

Paeoniflorin exerts antidepressant-like effects through enhancing neuronal FGF-2 by microglial inactivation

3 views | Apr 23 2021

Jie Cheng et al. found that paeoniflorin exhibited neuroprotective and antidepressant effects in mice, which might be mediated by activating neuronal FGF-2/FGFR1 signaling via the inhibition of microglial activation in the hippocampus. [Read the Full Post]

Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In Vitro

2 views | Apr 20 2021

Menghuan Guo et al. suggested that CED could induce apoptosis and G1 phase cell cycle arrest in A549 cells. [Read the Full Post]

Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis

2 views | Apr 20 2021

Wenlin Chen et al. indicated that bevacizumab (BEV) plus CCNU and regorafenib had a higher efficacy on the ORR, 6-m PFS rate and OS, and that BEV monotherapy or BEV combined with active drug therapies was advantageous for the ORR and 6-m PFS rate. [Read the Full Post]

Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition

3 views | Apr 13 2021

Narges K Gortany et al.indicated that foretinib might have the therapeutic potential against human GBM which deserve further investigation. [Read the Full Post]

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma

4 views | Apr 02 2021

Robert Hanes et al. supported LY2874455 as a better therapy than NVP-BGJ398 for FRS2-amplified liposarcoma, and a clinical trial was warranted. [Read the Full Post]

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial

12 views | Feb 19 2021

C Dinkic et al. thought that Pazopanib 600mg daily p.o. and metronomic cyclophosphamide 50mg daily p.o. was a feasible regimen for patients with recurrent platinum-resistant EOC and showed promising activity in this previously treated patient population. [Read the Full Post]

Altered TGFβ/SMAD Signaling in Human and Rat Models of Pulmonary Hypertension: An Old Target Needs Attention

14 views | Jan 20 2021

Takayuki Jujo Sanada et al. demonstrated considerable discrepancies in TGFβ-SMAD signaling between iPAH and hPAH patients, as well as between patients and rats with experimental PAH. [Read the Full Post]

Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events

13 views | Jan 19 2021

Hideki Imano et al. found that activation of inflammasomes contributed to the idiosyncratic reactions associated with semaxanib and sorafenib. [Read the Full Post]

Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling

19 views | Jan 15 2021

Yixiu Zhao et al. thought that KLX had the potential to be developed as a topical drug to promote diabetic wound healing. [Read the Full Post]

Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma

19 views | Jan 08 2021

Wei Zhou et al. proposed a combinative strategy of RFA and anlotinib as a novel approach for successful management of LSCC. [Read the Full Post]